Notes And Other Explanatory Information [Abstract]

GenSight Biologics S.A. - Filing #5982864

Concept 2024-01-01 to
2024-12-31
Notes and other explanatory information [abstract]
Disclosure of accounting judgements and estimates [text block]
3
Disclosure of auditors' remuneration [text block]
Note 26:
Disclosure of authorisation of financial statements [text block]
The consolidated financial statements as of December 31, 2024 have been prepared under the responsibility of management of the Group and were approved on March 18, 2025 by the Board of Directors.
Disclosure of basis of consolidation [text block]
3
Disclosure of cash flow statement [text block]
Note 11:
Disclosure of commitments [text block]
Note 22:
Disclosure of credit risk [text block]
12
Disclosure of depreciation and amortisation expense [text block]
3
Disclosure of earnings per share [text block]
Note 24:
Disclosure of entity's operating segments [text block]
3
Disclosure of events after reporting period [text block]
Note 27:
Disclosure of fair value measurement [text block]
3
Disclosure of fair value of financial instruments [text block]
11
Disclosure of finance income (cost) [text block]
Note 20:
Disclosure of financial instruments [text block]
On June 20, 2024
Disclosure of financial instruments at fair value through profit or loss [text block]
Disclosure of financial risk management [text block]
Note 25:
Disclosure of first-time adoption [text block]
Disclosure of general and administrative expense [text block]
18
Disclosure of general information about financial statements [text block]
Note 1:
Disclosure of going concern [text block]
The Group’s future operations are highly dependent on a
Disclosure of impairment of assets [text block]
4
Disclosure of income tax [text block]
3
Disclosure of information about key management personnel [text block]
On June 3, 2024
Disclosure of inventories [text block]
4
Disclosure of issued capital [text block]
On February 8, 2024
Disclosure of leases [text block]
3
Disclosure of liquidity risk [text block]
Disclosure of market risk [text block]
Disclosure of material accounting policy information [text block]
Note 3:
Disclosure of other assets [text block]
Note 7:
Disclosure of other current assets [text block]
Note 8:
Disclosure of other non-current liabilities [text block]
Note 13:
Disclosure of other operating expense [text block]
Note 18:
Disclosure of other operating income [text block]
Note 17:
Disclosure of other provisions, contingent liabilities and contingent assets [text block]
Note 12:
Disclosure of research and development expense [text block]
Disclosure of revenue from contracts with customers [text block]
3
Disclosure of trade and other payables [text block]
Note 14:

Talk to a Data Expert

Have a question? We'll get back to you promptly.